Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Evens

Showing results (1-10 of 253) with videos related to

Pageof 26
Sort By:
Acta Psychiatrica Belgica|March 1, 1980
[Tiapridal and alcoholic detoxication (author's transl)]M Evens
Oncology (Williston Park, N.Y.)|December 9, 2010
Improving outcomes in PTLDAndrew M Evens
Lancet (London, England)|July 27, 2024
Enhancing the treatment landscape: PET-guided BrECADD for advanced-stage, classical Hodgkin lymphomaAndrew M Evens
Current Opinion in Oncology|January 1, 2005
Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancerAndrew M Evens
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Highlights in Hodgkin lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition: commentaryAndrew M Evens
British Journal of Haematology|December 23, 2024
An editorial introduction: A vision for the future of haematologyAndrew M Evens
Hematological Oncology|June 15, 2025
Newly Diagnosed Classical Hodgkin Lymphoma: Optimizing Outcomes in a New Therapeutic EraAndrew M Evens
British Journal of Haematology|December 28, 2018
Important new developments in Hodgkin LymphomaAndrew M Evens
Blood|November 28, 2014
The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage diseaseAndrew M Evens, Lale Kostakoglu
Hematology. American Society of Hematology. Education Program|February 20, 2015
The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage diseaseAndrew M Evens, Lale Kostakoglu
Pageof 26

Showing results (1-10 of 253) with videos related to

Sort By:
Pageof 26
Acta Psychiatrica Belgica|March 1, 1980
[Tiapridal and alcoholic detoxication (author's transl)]M Evens
Oncology (Williston Park, N.Y.)|December 9, 2010
Improving outcomes in PTLDAndrew M Evens
Lancet (London, England)|July 27, 2024
Enhancing the treatment landscape: PET-guided BrECADD for advanced-stage, classical Hodgkin lymphomaAndrew M Evens
Current Opinion in Oncology|January 1, 2005
Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancerAndrew M Evens
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Highlights in Hodgkin lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition: commentaryAndrew M Evens
British Journal of Haematology|December 23, 2024
An editorial introduction: A vision for the future of haematologyAndrew M Evens
Hematological Oncology|June 15, 2025
Newly Diagnosed Classical Hodgkin Lymphoma: Optimizing Outcomes in a New Therapeutic EraAndrew M Evens
British Journal of Haematology|December 28, 2018
Important new developments in Hodgkin LymphomaAndrew M Evens
Blood|November 28, 2014
The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage diseaseAndrew M Evens, Lale Kostakoglu
Hematology. American Society of Hematology. Education Program|February 20, 2015
The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage diseaseAndrew M Evens, Lale Kostakoglu
Pageof 26